KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $757086.0.

  • Inovio Pharmaceuticals' Share-based Compensation fell 3893.77% to $757086.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 4292.08%. This contributed to the annual value of $6.6 million for FY2024, which is 4043.7% down from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Share-based Compensation stood at $757086.0 for Q3 2025, which was down 3893.77% from $834792.0 recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Share-based Compensation ranged from a high of $9.6 million in Q1 2021 and a low of $757086.0 during Q3 2025
  • Over the past 5 years, Inovio Pharmaceuticals' median Share-based Compensation value was $2.9 million (recorded in 2023), while the average stood at $3.7 million.
  • In the last 5 years, Inovio Pharmaceuticals' Share-based Compensation surged by 13980.56% in 2021 and then crashed by 6499.55% in 2023.
  • Inovio Pharmaceuticals' Share-based Compensation (Quarter) stood at $5.5 million in 2021, then crashed by 40.18% to $3.3 million in 2022, then plummeted by 30.79% to $2.3 million in 2023, then crashed by 41.94% to $1.3 million in 2024, then plummeted by 42.46% to $757086.0 in 2025.
  • Its last three reported values are $757086.0 in Q3 2025, $834792.0 for Q2 2025, and $1.4 million during Q1 2025.